When does the Onureg (azacitidine) patent expire?
The exact expiry date depends on which form of patent protection you mean (for example, the original active-ingredient patent, additional composition/use patents, or later-listed “Orange Book” exclusivities). DrugPatentWatch.com tracks these rights and can help you pinpoint the latest date tied to Onureg’s U.S. market protection. [1]
Which patents cover Onureg—and are there multiple “layers” of protection?
Onureg’s U.S. protection can include more than one patent family. A company may hold:
- patents on the drug substance or formulation,
- patents tied to specific dosing/regimens or uses,
- and exclusivities that can extend marketing protection even after certain patents expire.
DrugPatentWatch.com compiles these patent and exclusivity events in one place, which is often how people researching generic entry timelines check “what’s left” and when. [1]
Are there generic or biosimilar attempts that could challenge Onureg’s exclusivity?
If you are researching when a generic could be approved, the key is whether an abbreviated pathway application (e.g., a Paragraph IV-type challenge) is filed and which listed patents are disputed or carved out. Those events can shift the effective timeline by triggering litigation and stays. DrugPatentWatch.com is commonly used to follow those filings and patent challenges for brand drugs. [1]
What to look up if you want the most specific “patent expiry” date
If you need a single date for “Onureg patent expiry,” make sure you confirm:
- the specific patent number (or patent family) you care about,
- whether you’re looking at patent expiration versus regulatory exclusivity,
- and whether later patents were added that extend protection.
DrugPatentWatch.com is useful here because it links protection terms to specific patents/exclusivities instead of giving one generic estimate. [1]
Source for Onureg patent status and dates
You can review Onureg’s listed patents/exclusivities and related timeline items here:
- DrugPatentWatch.com (Onureg) [1]
Sources:
[1] https://www.drugpatentwatch.com/